Taming expectations of metformin as a treatment to extend healthspan

Adam Richard Konopka, Benjamin F. Miller

Research output: Contribution to journalReview article

Abstract

The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow aging in humans. While the Targeting Aging with Metformin (TAME) proposal and other small-scale clinical trials have the potential to support aging as a treatment indication, we propose that the goals of the TAME trial might not be entirely consistent with the Geroscience goal of extending healthspan. There is expanding epidemiological support for the health benefits of metformin in individuals already diagnosed with overt chronic disease. However, it remains to be understood if these protective effects extend to those free of chronic disease. Within this editorial, we seek to highlight critical gaps in knowledge that should be considered when testing metformin as a treatment to target aging.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalGeroScience
Volume41
Issue number2
DOIs
StatePublished - Apr 15 2019

Fingerprint

Metformin
Chronic Disease
Insurance Benefits
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Aging
  • Healthspan
  • Metformin
  • Slowed aging

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Taming expectations of metformin as a treatment to extend healthspan. / Konopka, Adam Richard; Miller, Benjamin F.

In: GeroScience, Vol. 41, No. 2, 15.04.2019, p. 101-108.

Research output: Contribution to journalReview article

Konopka, Adam Richard ; Miller, Benjamin F. / Taming expectations of metformin as a treatment to extend healthspan. In: GeroScience. 2019 ; Vol. 41, No. 2. pp. 101-108.
@article{69a3bcf9988a453b957e839edf175250,
title = "Taming expectations of metformin as a treatment to extend healthspan",
abstract = "The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow aging in humans. While the Targeting Aging with Metformin (TAME) proposal and other small-scale clinical trials have the potential to support aging as a treatment indication, we propose that the goals of the TAME trial might not be entirely consistent with the Geroscience goal of extending healthspan. There is expanding epidemiological support for the health benefits of metformin in individuals already diagnosed with overt chronic disease. However, it remains to be understood if these protective effects extend to those free of chronic disease. Within this editorial, we seek to highlight critical gaps in knowledge that should be considered when testing metformin as a treatment to target aging.",
keywords = "Aging, Healthspan, Metformin, Slowed aging",
author = "Konopka, {Adam Richard} and Miller, {Benjamin F.}",
year = "2019",
month = "4",
day = "15",
doi = "10.1007/s11357-019-00057-3",
language = "English (US)",
volume = "41",
pages = "101--108",
journal = "GeroScience",
issn = "2509-2715",
publisher = "Springer International Publishing AG",
number = "2",

}

TY - JOUR

T1 - Taming expectations of metformin as a treatment to extend healthspan

AU - Konopka, Adam Richard

AU - Miller, Benjamin F.

PY - 2019/4/15

Y1 - 2019/4/15

N2 - The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow aging in humans. While the Targeting Aging with Metformin (TAME) proposal and other small-scale clinical trials have the potential to support aging as a treatment indication, we propose that the goals of the TAME trial might not be entirely consistent with the Geroscience goal of extending healthspan. There is expanding epidemiological support for the health benefits of metformin in individuals already diagnosed with overt chronic disease. However, it remains to be understood if these protective effects extend to those free of chronic disease. Within this editorial, we seek to highlight critical gaps in knowledge that should be considered when testing metformin as a treatment to target aging.

AB - The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow aging in humans. While the Targeting Aging with Metformin (TAME) proposal and other small-scale clinical trials have the potential to support aging as a treatment indication, we propose that the goals of the TAME trial might not be entirely consistent with the Geroscience goal of extending healthspan. There is expanding epidemiological support for the health benefits of metformin in individuals already diagnosed with overt chronic disease. However, it remains to be understood if these protective effects extend to those free of chronic disease. Within this editorial, we seek to highlight critical gaps in knowledge that should be considered when testing metformin as a treatment to target aging.

KW - Aging

KW - Healthspan

KW - Metformin

KW - Slowed aging

UR - http://www.scopus.com/inward/record.url?scp=85061354633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061354633&partnerID=8YFLogxK

U2 - 10.1007/s11357-019-00057-3

DO - 10.1007/s11357-019-00057-3

M3 - Review article

C2 - 30746605

AN - SCOPUS:85061354633

VL - 41

SP - 101

EP - 108

JO - GeroScience

JF - GeroScience

SN - 2509-2715

IS - 2

ER -